Allergy shots for dust mite allergies tested in a special room
Part of Immune system & allergy clinical trials.
This trial tests if allergy shots (allergen-specific immunotherapy) can reduce symptoms of moderate to severe dust mite allergy. You will be in a room that exposes you to dust mites to see how well the treatment works, compared to a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have moderate to severe hay fever or eye allergies caused by dust mites, with or without mild asthma.
- Your dust mite allergy is confirmed by a positive skin prick test or blood test.
- You have had symptoms for at least 2 years, mostly during fall and winter or year-round.
- You have not had allergy shots for dust mites in the last 5 years.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a dust-mite allergy extract (“allergy shots”) to see if it safely reduces symptoms from dust-mite–driven hay fever (rhinitis/rhinoconjunctivitis), and possibly asthma symptoms. If you qualify, it may help your immune system tolerate dust mites better over time.
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
This trial tests allergy shots for children with dust mite allergies causing rhinitis or asthma. It aims to see if guiding treatment with detailed allergy testing leads to better results.
This trial tests allergy drops placed under the tongue to treat allergic rhinitis caused by house dust mites. It aims to see if the drops can safely reduce symptoms like sneezing and stuffy nose.
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
This study tests whether heating tissue in the nose (radiofrequency ablation) followed by allergy treatment under the skin (immunotherapy) can reduce long-lasting nasal congestion from dust mite allergy. It may help patients whose symptoms are severe and who have not been able to get enough relief with recent allergy medicines.
Hear when a new Allergic Rhinoconjunctivitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.